Rapt Therapeutics, INC Schedule 13G passive stakes

OrbiMed Advisors LLC has filed an amendment to its Schedule 13G, reporting a 0% beneficial ownership stake in RAPT Therapeutics, Inc.

RTW Investments, LP and Roderick Wong have filed a Schedule 13G, reporting no beneficial ownership of RAPT Therapeutics, Inc. common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong, M.D. have reported a 5.9% beneficial ownership stake in RAPT Therapeutics, Inc. common stock.

Deep Track Capital and affiliates report a 0.40% beneficial ownership in RAPT Therapeutics, Inc. common stock as of December 31, 2025.

Glazer Capital, LLC and Paul J. Glazer have reported a 5.36% beneficial ownership stake in RAPT Therapeutics, Inc. common stock.

OrbiMed Advisors LLC has reported a 6.6% beneficial ownership stake in RAPT Therapeutics, Inc., holding 1,086,618 shares of common stock.

Nantahala Capital Management and its managing members have reduced their beneficial ownership in RAPT Therapeutics, Inc. to 3.77% of common stock.

Biotechnology Value Fund and its affiliates have reported a complete divestment of their beneficial ownership in RAPT Therapeutics, Inc. as of September 30, 2025.

The Vanguard Group reported a 4.2% beneficial ownership stake in RAPT Therapeutics Inc. common stock as of September 30, 2025.

ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. have collectively reported a 7.4% beneficial ownership in RAPT Therapeutics, Inc.

Redmile Group, LLC and its affiliates reported a 9.9% beneficial ownership stake in RAPT Therapeutics, Inc. following a recent 1-for-8 reverse stock split and warrant adjustments.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a 5.75% beneficial ownership stake in RAPT Therapeutics, Inc.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 8.9% in Rapt Therapeutics, Inc., holding 11,764,000 shares of common stock.

The Vanguard Group has reported a 6.27% beneficial ownership stake in RAPT Therapeutics Inc., holding 8,278,798 shares of common stock as of March 31, 2025.

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, reporting a 1.7% beneficial ownership stake in RAPT Therapeutics, Inc. as of March 31, 2025.

Redmile Group, LLC and its affiliates have disclosed a 9.9% beneficial ownership stake in RAPT Therapeutics, Inc., totaling 13,932,449 shares, subject to a 9.99% beneficial ownership limitation on warrant exercises.

OrbiMed Advisors LLC has reported a 9.9% passive ownership stake in RAPT Therapeutics, Inc., holding 13,135,260 shares as of December 31, 2024.

Perceptive Advisors LLC and its affiliates have reported a 4.5% beneficial ownership stake in RAPT Therapeutics, Inc., holding 5,880,000 shares of common stock as of December 31, 2024.

The Vanguard Group has filed an Amendment No. 3 to its Schedule 13G, reporting a 2.22% beneficial ownership stake in RAPT Therapeutics Inc. as of January 31, 2025.

The Vanguard Group has filed an Amendment No. 3 to its Schedule 13G, reporting a 2.22% beneficial ownership stake in RAPT Therapeutics Inc. as of January 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, confirming a passive beneficial ownership of 0.4% of RAPT Therapeutics Inc.'s common stock as of January 31, 2025.

A group of investment entities led by Mark N. Lampert, including Biotechnology Value Fund L.P. and its affiliates, has disclosed a combined beneficial ownership of 8.7% of RAPT Therapeutics, Inc.'s common stock, including shares underlying pre-funded warrants.

Medicxi IV LP, Medicxi Co-Invest IV LP, and their related entities have disclosed a combined beneficial ownership of 16.9% of RAPT Therapeutics, Inc.'s common stock.

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have jointly disclosed a beneficial ownership of 9.99% in RAPT Therapeutics, Inc., totaling 13,193,110 shares.